P
MEDP icon

Palladiem’s Medpace MEDP Stock Holding History

Palladiem’s Portfolio MEDP Stock Details MEDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-175
Closed -$87.8K – 157
2026
Q1 		$87.8K Hold
175
– – 0.08% 76
2025
Q4 		$99.5K Buy
+175
New +$99.3K 0.09% 78

Other funds holding MEDP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Palladiem's MEDP Position: Q2 2026 in Review

Palladiem sold out of Medpace (MEDP) in Q2 2026, closing a stake of 175 shares — an estimated $87.8K sold.

Palladiem first reported a position in MEDP in Q4 2025 and held it in 2 quarters. The position peaked at $99.5K in Q4 2025. 695 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.

  • Palladiem reported no remaining Medpace position as of Q2 2026 after selling out during the quarter.
  • Palladiem sold 175 Medpace shares in Q2 2026, an estimated $87.8K.
  • Palladiem first reported a position in Medpace in Q4 2025 and held it in 2 quarters.
  • Palladiem's Medpace position peaked at $99.5K in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Medpace as of Q2 2026.

Based on Palladiem's 13F filing for Q2 2026, filed 13 Aug 2026.